Chiara Cremolini
President
About
Chiara Cremolini is Associated Professor in Medical Oncology at University of Pisa. In 2008 she obtained degree in Medicine, in 2011 a second-level Master in Drugs’ Development, in 2014 a specialization in Medical Oncology, in 2018 a PhD in Clinical Pathophysiology at the University of Pisa.
She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative GONO group and, as a translational interest, she is especially involved in the identification of potential molecular predictors of benefit from systemic treatments. She has author and co-authored of 200 peer-reviewed publications regarding colorectal cancer and has received merit awards at different international meetings for her research activity.
Publications
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study
Future Oncol – 2023 Jul
doi: 10.2217/fon-2023-0406 – PubMed ID: 37577810
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation
J Clin Oncol. 2023 Aug 3
doi: 10.1200/JCO.23.00506 – PubMed ID: 37535876
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Clin Colorectal Cancer. 2023 Jun 11
doi: 10.1016/j.clcc.2023.06.002 – PubMed ID: 37429749
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
Eur J Cancer. 2023 Aug;
doi: 10.1016/j.ejca.2023.05.001 – PubMed ID: 37301718
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Clin Cancer Res. 2023 Jun 13
doi: 10.1158/1078-0432.CCR-22-3878 – PubMed ID: 37022350
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer. 2023 Apr
doi: 10.1136/jitc-2022-006633 – PubMed ID: 37085190
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
Cancer Med. 2023 Apr
doi: 10.1002/cam4.5699 – PubMed ID: 36880426
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development
Br J Cancer. 2023 Mar
doi: 10.1038/s41416-023-02180-7 – PubMed ID: 36759721
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials Journal
ESMO Open – 2022
doi 10.1016/j.esmoop.2022.100606 – PubMed ID: 36327757
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials
European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.05.016 – PubMed ID: 35749909
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
Journal of Clinical Oncology – 2022
doi 10.1200/JCO.22.00839 – PubMed ID: 35666229